Skip to content

Comparative Study of the Effectiveness of the FraxPro Laser in Combination with Topical Desonide Compared to the Fraxpro Laser in combination with topical placebo in the Treatment of Patients with Axillary Hyperpigmentation Visiting the Razi Hospital

Comparative Study of the Effectiveness of the FraxPro Laser in Combination with Topical Desonide Compared to the Fraxpro Laser in combination with topical placebo in the Treatment of Patients with Axillary Hyperpigmentation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240621062202N1
Enrollment
24
Registered
2024-10-26
Start date
2024-12-05
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of axillary hyperpigmentation. Disorder of pigmentation, unspecified

Interventions

Intervention 1: Intervention group: People who are treated with local placebo and laser, the patients are instructed to shave their armpit area one day before the treatment and wash the area with wate

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adults between 18 and 65 years old Complying with study protocols and signing informed consent voluntarily Enthusiastic people and having the right cooperation for the next follow-up People with a diagnosis of axillary hyperpigmentation confirmed by a dermatologist (the skin of the axillary area has a color difference of at least 2 degrees with the skin of the surrounding area)

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Acanthosis nigricans Body mass index above 27 skin diseases with abnormal hyperpigmentation such as Riehl melanosis and lichen planus pigmentosa Patients undergoing chemotherapy treatment Patients treated with antiretroviral drugs Patients with shoulder pain or stiffness in the shoulder area for whom it is difficult to tolerate laser treatment Use of local treatments during the last 1 month Use of laser treatments in the past 2 months at the site Patients with active bacterial or viral infection in the treatment area History of skin cancers uncontrolled systemic disease Photosensitivity Seizure history History of hypertrophic and keloid scars

Design outcomes

Primary

MeasureTime frame
Illumination of the treated area. Timepoint: In addition to the basic visit, before each laser session (every 3 weeks), patients are also clinically evaluated 1 month after the last laser session. Method of measurement: Based on Von Luschan's chromatic classification criterion and its improvement rate is based on Luminosity difference between axilla and periaxilla in each session and comparing this score between sessions.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr Ifa Etesami

Tehran University of Medical Sciences

ifa.etesami@gmail.com+98 21 5563 0553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026